Novadien (Dienogest, Ethinylestradiol | Lactose Monohydrate)

• Novadien, a combined oral contraceptive, is indicated for hormonal contraception.
• Contraception (prevention of pregnancy): provides reliable, reversible birth control for women of child‑bearing age when taken as directed.
• Menstrual cycle regulation: helps establish regular monthly bleeding, reduces the length and volume of periods, and can lessen menstrual‑associated symptoms.
• Management of dysmenorrhea: alleviates painful menstrual cramps and improves quality of life for women experiencing moderate to severe dysmenorrhea.

• Novadien combines the progestogenic agent dienogest with the estrogen ethinylestradiol. Dienogest binds to progesterone receptors, suppressing the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, thereby preventing ovulation. Ethinylestradiol provides estrogenic activity that stabilises the endometrium and enhances the contraceptive effect, while also influencing cervical mucus to become less permeable to sperm. The combined hormonal action also reduces the likelihood of endometrial proliferation, contributing to overall contraceptive efficacy.

Novadien may be associated with a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Nausea
• Headache
• Breast tenderness
• Irregular vaginal bleeding

Serious or Rare Side Effects

• Deep vein thrombosis
• Pulmonary embolism
• Severe allergic reaction (anaphylaxis)

Before prescribing Novadien, clinicians should consider several precautionary measures to ensure patient safety.

• Contraindications: avoid use in women with known thromboembolic disorders, active liver disease, or hormone‑sensitive cancers.
• Smoking: advise against use in women over 35 who smoke, due to increased cardiovascular risk.
• Cardiovascular risk: assess history of hypertension, diabetes, or hyperlipidaemia before initiating therapy.
• Interactions: review concomitant medications that may affect clotting or hormone metabolism.
• Pregnancy and lactation: discontinue if pregnancy is confirmed; avoid initiating during breastfeeding unless benefits outweigh risks.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Novadien can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Combined hormonal contraceptives with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce efficacy, increasing risk of pregnancy.
• Anticoagulants (warfarin) may have altered plasma levels, requiring monitoring.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine) may increase risk of bleeding.

Moderate Interactions (Monitor Closely)

• Antiepileptic drugs (e.g., phenytoin) may modestly reduce contraceptive effect.
• Antibiotics such as tetracycline may have a slight impact on hormone levels.
• Herbal supplements containing St. John’s wort may decrease contraceptive reliability.